Last reviewed · How we verify
RBD1016
At a glance
| Generic name | RBD1016 |
|---|---|
| Also known as | RBD1016 injection |
| Sponsor | Ribocure Pharmaceuticals AB |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D (PHASE2)
- A Study of RBD1016 in CHB Participants (PHASE2)
- A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection (PHASE1)
- A Single Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of RBD1016 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RBD1016 CI brief — competitive landscape report
- RBD1016 updates RSS · CI watch RSS
- Ribocure Pharmaceuticals AB portfolio CI